This review highlights some of the many abstracts on lupus nephritis research presented at ACR Convergence 2025. They demonstrate advances made on early recognition of the condition, as well as offering some hope in terms of achieving better outcomes.
Research on PT for knee OA, HCQ’s protective role in lupus nephritis & the link between RA disease activity & frailty.
Handpicked Reviews of Contemporary Literature
The Johns Hopkins Lupus Center, Baltimore, has described its experience using hydroxychloroquine (HCQ) levels.1 Forty-four percent of its patients had levels below 500 ng/mL (partial nonadherence); 13% were severely nonadherent (<200 ng/mL). They were shown their results and educated on HCQ adherence. Adherence then improved to 80%; those with lower HCQ levels had higher disease…